Source link : https://newshealth.biz/health-news/anti-cd38-antibody-safe-effective-in-immune-thrombocytopenia/
The anti-CD38 monoclonal antibody mezagitamab had similar safety to placebo in patients with persistent or chronic immune thrombocytopenia. The drug also significantly increased platelet counts, a key secondary efficacy endpoint. Platelet response with mezagitamab was rapid — a mean of 4 days among patients who responded, and as fast as 2 days. Treatment with the […]
The post Anti-CD38 Antibody Safe, Effective in Immune Thrombocytopenia first appeared on News Health.
—-
Author : News Health
Publish date : 2026-04-08 21:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8